Is Sermorelin Legal in Kentucky? Federal Law, State Rules, and How to Get a Prescription
See the public record for Sermorelin
At a glance
- FDA approval / None. Geref's two approvals were withdrawn in 2009 [1]
- What is dispensed / Compounded sermorelin, not an FDA-approved product [2]
- FDA safety-risk list / Sermorelin is not on it [3]
- FDA list for state-licensed pharmacies / Sermorelin does not appear [4]
- Outsourcing-facility nominations / Sermorelin acetate is category 1, under evaluation [5]
- HHS peptide enforcement policy / Not one of the six named peptides [6]
- Sport / Prohibited at all times by WADA, S2.2.4 [7]
- Current approved dose / None [1][2]
What Is Sermorelin's Federal Status?
Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone; it signals the pituitary to release growth hormone and is not growth hormone itself [8].
FDA approved it as Geref under two applications: a 0.05 mg/ampule product approved December 28, 1990, for evaluating the pituitary's ability to secrete growth hormone, and 0.5 mg and 1 mg vials approved September 26, 1997, for treating idiopathic growth hormone deficiency in children with growth failure [1]. Geref was not approved for adults, anti-aging, weight loss or athletic performance [1].
The manufacturer, EMD Serono, discontinued Geref in 2008 and asked FDA to withdraw the applications; FDA withdrew both approvals effective June 18, 2009 [1]. In March 2013 FDA determined that Geref had not been withdrawn from sale for reasons of safety or effectiveness [1][9]. Those two applications are the only sermorelin applications in Drugs@FDA [9]. With them gone, sermorelin sold in the US today is compounded [2].
Where Does Sermorelin Sit on FDA's Compounding Lists?
- Sermorelin is not on FDA's list of bulk substances that may present significant safety risks [3]. That list does name two other growth-hormone-releasing peptides, GHRP-2 and GHRP-6, with immunogenicity and impurity concerns [3].
- On FDA's list of bulk substances nominated for outsourcing facilities, updated March 21, 2025, sermorelin acetate sits in category 1, under evaluation, and carries the list's mark for substances that are components of FDA-approved drugs [5].
- Sermorelin does not appear in any category on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [4].
- It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [6].
What About Kentucky?
Kentucky statutes, Board of Pharmacy rules and court decisions are not covered on this page. The federal status above is the documented status of any sermorelin product sold in the state: none is FDA-approved, and products available in the United States are compounded, which means FDA does not review them for safety, effectiveness or quality before they are marketed [1][2]. For product information, see sermorelin.
What Doses Appear in the Studies?
No sermorelin product is currently FDA-approved, so there is no current approved dose [1][2]. The doses below come from studies and are not recommended doses.
- Children with growth hormone deficiency: In a 1-year, open-label, multicenter trial, 110 previously untreated prepubertal children (86 evaluable) received 30 micrograms/kg subcutaneously once daily at bedtime. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were good responders at 6 months. Fasting glucose did not change, IGF-I was not excessively raised and sermorelin was well tolerated overall [10].
- Older men: 10 healthy men (mean age 68) received 0.5 mg or 1 mg subcutaneously twice daily for 14 days each. At the higher dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from those of 9 young men. This was a short physiology study, not a trial of clinical benefit [11].
Is Sermorelin Allowed in Sport?
No under anti-doping rules. WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, and prohibits it at all times, in and out of competition; S2 substances are non-Specified Substances, and sermorelin is also named in the 2027 List that takes effect January 1, 2027 [7][12].
Frequently asked questions
What is sermorelin's federal legal status?
Is sermorelin FDA-approved?
Is sermorelin on FDA's safety-risk list for compounded ingredients?
Can a Kentucky athlete use sermorelin?
What dose of sermorelin is approved?
References
Show all 12 referencesHide references
- Federal Register :: Request Access.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- U.S. Food and Drug Administration.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- World Anti-Doping Agency.